UNITY Biotechnology Inc

Change company Symbol lookup

Select an option...

UBX UNITY Biotechnology Inc

KEY KeyCorp

AMPX Amprius Technologies Inc

TPC Tutor Perini Corp

LTRN Lantern Pharma Inc

JGGC Jaguar Global Growth Corporation I

WHG Westwood Holdings Group Inc

BNOX Bionomics Ltd

PSO Pearson PLC

ERNA Eterna Therapeutics Inc

Go

Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.